Discovery and development of therapeutic aptamers.
暂无分享,去创建一个
[1] Scott D. Lewis,et al. Pharmacologic and Pharmacokinetic Assessment of Anti-TGFβ2 Aptamers in Rabbit Plasma and Aqueous Humor , 2006, Pharmaceutical Research.
[2] Markus Kurz,et al. Conjugation to polyethylene glycol polymer promotes aptamer biodistribution to healthy and inflamed tissues. , 2005, Oligonucleotides.
[3] Andrew D Ellington,et al. Aptamer therapeutics advance. , 2006, Current opinion in chemical biology.
[4] C. Won,et al. PEG-modified biopharmaceuticals , 2009 .
[5] B. Berridge,et al. Development of a Sensitive and Specific in Situ Hybridization Technique for the Cellular Localization of Antisense Oligodeoxynucleotide Drugs in Tissue Sections , 2007, Toxicologic pathology.
[6] P. Rosenfeld,et al. Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration , 2009, Current opinion in ophthalmology.
[7] Sanjay K. Jain,et al. PEGylation: an approach for drug delivery. A review. , 2008, Critical reviews in therapeutic drug carrier systems.
[8] R. Sousa,et al. A mutant T7 RNA polymerase as a DNA polymerase. , 1995, The EMBO journal.
[9] A D Ellington,et al. Aptamers as therapeutic and diagnostic reagents: problems and prospects. , 1997, Current opinion in chemical biology.
[10] J. Marquis,et al. Toxicological evaluation of oligonucleotide therapeutics. , 2000, Current opinion in molecular therapeutics.
[11] Petra Burgstaller,et al. GnRH binding RNA and DNA Spiegelmers: a novel approach toward GnRH antagonism. , 2002, Chemistry & biology.
[12] A. Macleod,et al. Identification and Partial Purification of Human Double Strand RNase Activity , 1998, The Journal of Biological Chemistry.
[13] Charles Wilson. Aptamer Opportunities and Challenges , 2007 .
[14] J. Szostak,et al. In vitro selection of RNA molecules that bind specific ligands , 1990, Nature.
[15] R. Buhmann,et al. Aptamers—basic research, drug development, and clinical applications , 2005, Applied Microbiology and Biotechnology.
[16] C. Mailhos,et al. Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. , 2006, The American journal of pathology.
[17] M. Pangburn,et al. Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action. , 1997, The Journal of pharmacology and experimental therapeutics.
[18] S. Steinhubl,et al. Phase 1b Randomized Study of Antidote-Controlled Modulation of Factor IXa Activity in Patients With Stable Coronary Artery Disease , 2008, Circulation.
[19] A. Levin,et al. Absolute bioavailability of 2'-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in rats. , 2001, The Journal of pharmacology and experimental therapeutics.
[20] S. Steinhubl,et al. First-in-Human Experience of an Antidote-Controlled Anticoagulant Using RNA Aptamer Technology: A Phase 1a Pharmacodynamic Evaluation of a Drug-Antidote Pair for the Controlled Regulation of Factor IXa Activity , 2006, Circulation.
[21] John O Trent,et al. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. , 2009, Experimental and molecular pathology.
[22] D. Wagner,et al. Inhibition of von Willebrand factor‐mediated platelet activation and thrombosis by the anti‐von Willebrand factor A1‐domain aptamer ARC1779 , 2009, Journal of thrombosis and haemostasis : JTH.
[23] K. Stecker,et al. In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration. , 1998, The Journal of pharmacology and experimental therapeutics.
[24] I. Roy,et al. Therapeutic applications of aptamers , 2008, Expert opinion on investigational drugs.
[25] L. Edvinsson,et al. Inhibitory effect of BIBN4096BS, CGRP8–37, a CGRP antibody and an RNA‐Spiegelmer on CGRP induced vasodilatation in the perfused and non‐perfused rat middle cerebral artery , 2007, British journal of pharmacology.
[26] F. Ducongé,et al. Aptamers against extracellular targets for in vivo applications. , 2005, Biochimie.
[27] A. Azadi,et al. Pharmacokinetic Consequences of Pegylation , 2006, Drug delivery.
[28] L. Gold,et al. Aptamers as therapeutic and diagnostic agents. , 2000, Journal of biotechnology.
[29] S. Klußmann,et al. Toward third-generation aptamers: Spiegelmers and their therapeutic prospects. , 2003, Current opinion in drug discovery & development.
[30] D. Kornbrust,et al. Oligodeoxynucleotide Studies in Primates: Antisense and Immune Stimulatory Indications , 2003, Toxicologic pathology.
[31] A. DeAnda,et al. Pilot study of the efficacy of a thrombin inhibitor for use during cardiopulmonary bypass. , 1994, The Annals of thoracic surgery.
[32] J P Sheehan,et al. Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex. , 1998, Blood.
[33] Francesco M Veronese,et al. PEGylation, successful approach to drug delivery. , 2005, Drug discovery today.
[34] Anthony D. Keefe,et al. SELEX with modified nucleotides. , 2008, Current opinion in chemical biology.
[35] R. Becker,et al. A randomized, repeat‐dose, pharmacodynamic and safety study of an antidote‐controlled factor IXa inhibitor , 2008, Journal of thrombosis and haemostasis : JTH.
[36] T. Mccauley,et al. Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102. , 2007, Cancer research.
[37] A. Levin,et al. Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide. , 2002, International immunopharmacology.
[38] P. Nicklin,et al. Pharmacokinetics, metabolism, and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration. , 1997, Biochemical pharmacology.
[39] B. Sullenger,et al. The potential of aptamers as anticoagulants. , 2005, Trends in cardiovascular medicine.
[40] H. Anders,et al. Ccl2/Mcp‐1 blockade reduces glomerular and interstitial macrophages but does not ameliorate renal pathology in collagen4A3‐deficient mice with autosomal recessive Alport nephropathy , 2009, The Journal of pathology.
[41] F. Veronese,et al. The Impact of PEGylation on Biological Therapies , 2012, BioDrugs.
[42] A. Levin,et al. Basic Principles of the Pharmacokinetics of Antisense Oligonucleotide Drugs , 2007 .
[43] G. Hartmann,et al. Accessing the therapeutic potential of immunostimulatory nucleic acids. , 2008, Current opinion in immunology.
[44] G. Shopp,et al. Short communication: renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins. , 1998, Toxicological sciences : an official journal of the Society of Toxicology.
[45] D. Guyer,et al. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease , 2006, Nature Reviews Drug Discovery.
[46] S. Klußmann,et al. Ghrelin neutralization by a ribonucleic acid-SPM ameliorates obesity in diet-induced obese mice. , 2006, Endocrinology.
[47] L. Kèlland,et al. Discovery and development of anticancer aptamers , 2006, Molecular Cancer Therapeutics.
[48] R A Bendele,et al. Derivation of RNA aptamer inhibitors of human complement C5. , 1999, Immunopharmacology.
[49] E. Spicer,et al. The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells. , 2008, Cancer research.
[50] [14] In vitro selection of RNA aptamers , 2000 .
[51] Joyce Nelson,et al. Pharmacokinetics and Safety of an Anti-Vascular Endothelial Growth Factor Aptamer (NX1838) Following Injection into the Vitreous Humor of Rhesus Monkeys , 2000, Pharmaceutical Research.
[52] G. Hardee,et al. Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2'-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[53] M. Tschöp,et al. Inhibition of ghrelin action in vitro and in vivo by an RNA-Spiegelmer. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[54] L. Gold,et al. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. , 1990, Science.
[55] J. M. Healy,et al. First-in-Human Evaluation of Anti–von Willebrand Factor Therapeutic Aptamer ARC1779 in Healthy Volunteers , 2007, Circulation.
[56] A. Levin,et al. Comparison of the pharmacokinetics of subcutaneous and intravenous administration of a phosphorothioate oligodeoxynucleotide in cynomolgus monkeys. , 2000, Antisense & nucleic acid drug development.